The $650,000 partnership hopes to reduce manufacturing cost and increase immunoactivity for iPSC-derived allogenic cancer immunotherapies. The strategic partnership between UK-based Plasticell and Singapore-based LambdaGen will develop induced pluripotent stem cell (iPSCs) derived chimeric antigen receptor-natural killer (CAR-NK) allogenic cancer immunotherapies. The collaboration is funded by EUREKA GlobalStars, an international research and development funding program. LambdaGen will be responsible for generating the iPSC lines engineered with CARs that enhance the anti-tumor activity of the body’s immune cells. Plasticell will use…